TempraMed provides last-mile control and management solutions to protect patients from temperature-sensitive medications.
TempraMed has raised $1.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
TempraMed is headquartered in Sammamish, United States.
TempraMed provides last-mile control and management solutions to protect patients from temperature-sensitive medications.
TempraMed is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TempraMed — Funding & Investors." VCBacked, October 21, 2025, https://www.vcbacked.co/company/tempramed. Accessed August 24, 2026.
VCBacked. (2025). TempraMed — Funding & Investors. Retrieved August 24, 2026, from https://www.vcbacked.co/company/tempramed
{{cite web |title=TempraMed — Funding & Investors |url=https://www.vcbacked.co/company/tempramed |website=VCBacked |access-date=August 24, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated